InMed Pharmaceuticals (INM)
NASDAQ:INM
Want to see INM full AI Analyst Report?
Top Page
InMed Pharmaceuticals
(NASDAQ:INM)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.50
▲(33.93% Upside)
Action:Reiterated
Date:06/11/26
The score is held back primarily by weak fundamentals—ongoing losses and sharply negative operating/free cash flow—despite a low-leverage balance sheet. Technicals are constructive with price strength and positive momentum indicators, while valuation is constrained by negative earnings and no stated dividend. Corporate events reduce near-term listing risk and add strategic optionality, but come with significant dilution and deal-execution risk.
Positive Factors
Conservative balance sheet
Very low leverage reduces refinancing pressure and preserves financial optionality over the next 2–6 months. This balance sheet flexibility helps the company fund R&D or bridge financings for development programs without immediate covenant risk, supporting durability through clinical timelines.
Negative Factors
Negative cash flow / burn
Deeply negative operating and free cash flow indicate the company is burning cash rather than generating it, increasing reliance on external financing. Persistent cash outflows constrain the ability to advance multiple programs, elevate dilution risk, and reduce flexibility across clinical and manufacturing investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage reduces refinancing pressure and preserves financial optionality over the next 2–6 months. This balance sheet flexibility helps the company fund R&D or bridge financings for development programs without immediate covenant risk, supporting durability through clinical timelines.
Read all positive factors
InMed Pharmaceuticals Key Performance Indicators (KPIs)
InMed Pharmaceuticals (INM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.00M
Dividend YieldN/A
Average Volume (3M)113.41K
Price to Earnings (P/E)―
Beta (1Y)3.41
Revenue Growth-34.06%
EPS Growth79.61%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1142.54
Shares Outstanding3,314,063
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap-0.38
Enterprise Value/Revenue-0.47
Enterprise Value/Gross Profit-1.55
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InMed Pharmaceuticals Business Overview & Revenue Model
Company Description
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topi...
How the Company Makes Money
InMed’s business model has historically centered on advancing its internally developed pharmaceutical candidates (cannabinoid-based drug programs) and monetizing its cannabinoid manufacturing capabilities. Potential revenue sources include: (1) sa...
InMed Pharmaceuticals Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
78
Positive
Cash Flow
12
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.02M | 4.94M | 4.60M | 4.14M | 1.09M | 0.00 |
| Gross Profit | 1.22M | 1.71M | 1.10M | 1.40M | 543.55K | 0.00 |
| EBITDA | -9.23M | -7.26M | -7.06M | -7.34M | -18.09M | -12.17M |
| Net Income | -9.91M | -8.16M | -7.68M | -7.95M | -18.60M | -12.65M |
Balance Sheet | ||||||
| Total Assets | 9.13M | 21.23M | 16.17M | 18.69M | 16.46M | 12.10M |
| Cash, Cash Equivalents and Short-Term Investments | 5.20M | 15.09M | 8.99M | 11.81M | 8.01M | 9.16M |
| Total Debt | 420.15K | 1.01M | 1.32M | 518.92K | 1.02M | 333.64K |
| Total Liabilities | 2.24M | 2.92M | 3.58M | 2.67M | 4.78M | 2.97M |
| Stockholders Equity | 6.89M | 18.30M | 12.59M | 16.02M | 11.69M | 9.12M |
Cash Flow | ||||||
| Free Cash Flow | -9.01M | -7.77M | -7.00M | -7.45M | -15.62M | -9.79M |
| Operating Cash Flow | -9.01M | -7.77M | -6.99M | -7.28M | -15.58M | -9.79M |
| Investing Cash Flow | 0.00 | 0.00 | -9.29K | -661.80K | -673.00K | -1.73K |
| Financing Cash Flow | 8.22M | 12.27M | 4.65M | 10.68M | 15.07M | 10.85M |
InMed Pharmaceuticals Technical Analysis
Positive
1.12
Price Trends
1.02
Positive
0.95
Positive
1.34
Positive
Market Momentum
0.16
Positive
61.29
Neutral
39.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INM, the sentiment is Positive. The current price of 1.12 is below the 20-day moving average (MA) of 1.50, above the 50-day MA of 1.02, and below the 200-day MA of 1.34, indicating a bullish trend. The MACD of 0.16 indicates Positive momentum. The RSI at 61.29 is Neutral, neither overbought nor oversold. The STOCH value of 39.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INM.
InMed Pharmaceuticals Risk Analysis
InMed Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. InMed Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InMed Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.00M | -0.62 | -82.17% | ― | -34.06% | 79.61% | |
| ― | $5.52M | -1.07 | -165.94% | ― | -70.00% | 14.70% | |
49 Neutral | $7.33M | -3.28 | -60.33% | ― | 23.52% | 48.34% | |
42 Neutral | $3.69M | -0.15 | -386.72% | ― | -24.36% | 47.35% |
* Healthcare Sector Average
INM
InMed Pharmaceuticals
1.51
-0.86
-36.29%
TCRT
Alaunos Therapeutics
2.28
-0.92
-28.75%
XBIO
Xenetic Biosciences
3.24
0.44
15.71%
ENSC
Ensysce Biosciences
0.27
-1.88
-87.49%
KTTA
Pasithea Therapeutics Corp
0.56
-0.21
-27.27%
InMed Pharmaceuticals Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status
Positive
Jun 10, 2026
InMed Pharmaceuticals Inc., a developer of small molecule therapies targeting CB1/CB2 receptors with programs in Alzheimer’s, ocular and dermatological diseases, has clarified its Nasdaq listing status following earlier compliance concerns. ...
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
InMed Pharmaceuticals Announces Reverse Merger with Mentari Therapeutics
Positive
May 19, 2026
On May 19, 2026, InMed Pharmaceuticals and privately held Mentari Therapeutics signed a definitive all‑stock merger agreement that will see Mentari’s migraine‑focused pipeline combined with InMed’s public listing, with the ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
InMed Pharmaceuticals Lowers Exercise Price on Preferred Options
Neutral
May 19, 2026
On May 18, 2026, InMed Pharmaceuticals Inc. amended the terms of certain preferred investment options held by Armistice Capital Master Fund Ltd., reducing the exercise price for up to 278,761 common shares from $16.60 to $0.80 per share, reflectin...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
InMed Highlights INM-901 Alzheimer’s Data in Q3 Update
Negative
May 7, 2026
On May 6, 2026, InMed Pharmaceuticals reported third-quarter fiscal 2026 results for the period ended March 31, 2026, highlighting new preclinical data showing its INM-901 candidate reduced neuroinflammation in advanced 3D human brain organoid mod...
Business Operations and StrategyPrivate Placements and Financing
InMed Pharmaceuticals Reprices Investment Options to Attract Capital
Positive
Apr 27, 2026
On April 21 and April 24, 2026, InMed Pharmaceuticals entered into amending agreements to significantly reduce the exercise prices on existing preferred investment options held by Sabby Volatility Warrant Master Fund and three affiliates of H.C. W...
Private Placements and FinancingRegulatory Filings and Compliance
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing
Neutral
Apr 3, 2026
InMed Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing pharmaceutical products and managing its publicly traded common shares, continues to utilize capital markets instruments as part of its financing str...
Delistings and Listing ChangesRegulatory Filings and Compliance
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Mar 30, 2026
On March 27, 2026, InMed Pharmaceuticals disclosed it had received a Nasdaq notification that its common shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive trading days between February 11 and March 26, 2026. The comp...
Business Operations and StrategyProduct-Related Announcements
InMed Reports Positive Preclinical Data for Alzheimer’s Candidate
Positive
Mar 23, 2026
On March 23, 2026, InMed Pharmaceuticals reported positive preclinical data showing its INM-901 candidate significantly reduced neuroinflammation in advanced 3D human brain organoid models of Alzheimer’s disease. The results, generated with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.